FAQ

N,N-didesmethyl-4-hydroxytamoxifen

Known as: norendoxifen 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2018
012320112018

Related topics

Related topics

1 relation

Broader (1)

Tamoxifen

Related mentions per year

Related mentions per year

1955-2018
1960198020002020
N,N-didesmethyl-4-hydroxytamoxifen
Tamoxifen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro.
Norendoxifen, an active metabolite of tamoxifen, is a potent aromatase inhibitor. Little information is available regarding… (More)
Is this relevant?
2016
2016
Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
AIM The aim was to examine the influence of CYP2C19 variants and associated haplotypes on the disposition of tamoxifen and its… (More)
Is this relevant?
2016
2016
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
The design and synthesis of dual aromatase inhibitors/selective estrogen receptor modulators (AI/SERMs) is an attractive strategy… (More)
Is this relevant?
2016
2016
Tamoxifen in the Mouse Brain: Implications for Fate-Mapping Studies Using the Tamoxifen-Inducible Cre-loxP System
The tamoxifen-inducible Cre-loxP system is widely used to overcome gene targeting pre-adult lethality, to modify a specific cell… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
Both selective estrogen receptor modulators and aromatase inhibitors are widely used for the treatment of breast cancer… (More)
Is this relevant?
2013
2013
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
The first synthesis of the tamoxifen metabolite norendoxifen is reported. This included syntheses of (E)-norendoxifen, (Z… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2013
2013
Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.
Aromatase catalyzes the conversion of testosterone to estradiol and is the main source of endogenous estrogen in postmenopausal… (More)
  • table 1
Is this relevant?
2013
2013
Dmd052506 1715..1720
Aromatase catalyzes the conversion of testosterone to estradiol and is the main source of endogenous estrogen in postmenopausal… (More)
  • figure 2
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2011
2011
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?